Intellia Therapeutics, Inc. (NTLA)
| Market Cap | 1.56B |
| Revenue (ttm) | 67.67M |
| Net Income (ttm) | -412.69M |
| Shares Out | 118.13M |
| EPS (ttm) | -3.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,093,282 |
| Open | 12.82 |
| Previous Close | 13.04 |
| Day's Range | 12.72 - 14.16 |
| 52-Week Range | 6.83 - 28.25 |
| Beta | 1.99 |
| Analysts | Buy |
| Price Target | 20.02 (+51.67%) |
| Earnings Date | May 7, 2026 |
About NTLA
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis;... [Read more]
Financial Performance
In 2025, Intellia Therapeutics's revenue was $67.67 million, an increase of 16.92% compared to the previous year's $57.88 million. Losses were -$412.69 million, -20.49% less than in 2024.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price target is $20.02, which is an increase of 51.67% from the latest price.
News
Intellia Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Intellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To Test
Intellia Therapeutics Inc. (NASDAQ:NTLA) shares are up on Monday after the company announced a rolling BLA submission to the FDA for its gene-editing therapy, lonvo-z (NTLA-2002), which is aimed at tr...
Intellia Therapeutics Transcript: Study result
The phase III HAELO trial showed that a single dose of lonvo-z, an in vivo CRISPR-based gene-editing therapy, led to an 87% reduction in HAE attack rates and 62% of patients being attack- and therapy-free at six months, with a favorable safety profile. Early crossover data suggest further improvements over time. Additional long-term data and subgroup analyses will be presented at EAACI.
Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial
Intellia Therapeutics said on Monday its experimental therapy for a rare genetic disorder has met the main goal in a late-stage study.
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition succeeded in a Phase 3 trial, a landmark for gene editing. The treatment uses Nobel Prize-winning Crispr technology ...
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from bot...
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Intellia Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Pivotal Phase III HAELO study data is expected mid-year, targeting a first-in-class in vivo gene editing launch next year. The product aims for high efficacy, durable attack-free outcomes, and strong commercial positioning, with a straightforward manufacturing process and significant cost-saving potential for healthcare systems.
Intellia Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
lonvo-z for HAE is nearing Phase III completion with strong efficacy and safety, aiming for a 2027 U.S. launch. TTR programs have resumed after safety enhancements, and commercial preparations are underway for a high-margin, premium-priced product.
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial
Intellia Therapeutics Inc. (NASDAQ: NTLA) shares are up on Monday following the FDA's decision to lift the clinical hold on its MAGNITUDE Phase 3 clinical trial.
US FDA lifts clinical hold on Intellia's heart disease gene therapy trial
Intellia Therapeutics said on Monday the U.S. Food and Drug Administration has removed a clinical hold on the late-stage clinical trial for its experimental gene therapy for a heart disease.
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Intellia Therapeutics Earnings Call Transcript: Q4 2025
Rapid progress in phase 3 trials for HAE and ATTR amyloidosis, with strong patient and physician interest in lonvo-z. Financials improved year-over-year, and commercial launch preparations are underway. MAGNITUDE-2 hold lifted, but MAGNITUDE remains on FDA hold pending further review.
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther...
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther...
Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder
The U.S. Food and Drug Administration (FDA) on Tuesday said it removed the clinical hold on Intellia Therapeutics Inc.‘s (NASDAQ: NTLA) Investigational New Drug application (IND) for the MAGNITUDE-2 P...
US FDA lifts clinical hold on Intellia's nerve disease trail
Intellia Therapeutics said on Tuesday that the U.S. Food and Drug Administration has lifted a clinical hold on one of its gene therapy late-stage trial, allowing the company to resume testing its expe...
Intellia Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Late-stage programs for HAE and TTR amyloidosis show strong efficacy and safety, with Lombozi poised for a 2027 launch and Nexi aiming to resume phase 3 after resolving a clinical hold. Market and payer feedback is highly favorable, and the company is well-funded.
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...